SecBot SecBot
PRESS-RELEASE ·Filed Nov 4, 2026

KURA

Kura Oncology, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed12d 17h ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

Monitor ASH presentations for efficacy and safety data on ziftomenib combinations, particularly FLT3 inhibitor combinations and longer-term frontline data, which could de-risk the Phase 3 KOMET-017 study and expand the addressable patient population.

DirectionNeutral
Confidencemedium
Horizonweeks

KOMZIFTI

◆ Mixed Named in this press release
Impact
Phase
Approved
Time to market
Already approved and commercially available in the U.S. since November 2025.
Next catalyst
None dated

What to watchKOMZIFTI is already approved and generating growing revenue, so the defining binary event has passed. Watch for ASH 2026 (December 2026) where ziftomenib combination data in newly diagnosed AML will be presented -- strong data could support a major label-expansion opportunity into the frontline setting, while weak data would cap the upside thesis. Also track quarterly sales growth trajectory as the key near-term value driver.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$7.61
T+0 close · Nov 4, 2026 · via day close
Latest settled
+1.58%
T+5 · $7.73 · next T+20 in 16d
Vs SPY
+2.49%
α at T+5
Latest observation
−3.93%
T+8 · FF3 residual α
  1. T+0 · Nov 4 $7.61entry
  2. T+1 · 12d ago −10.64%α −6.23% · $6.80
  3. T+5 · 6d ago +1.58%α +2.49% · $7.73
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kura Oncology and Kyowa Kirin announced that eight abstracts on ziftomenib, including four oral presentations, were accepted for the 2026 ASH Annual Meeting. The presentations include first clinical data on ziftomenib combined with FLT3 inhibitors (quizartinib and gilteritinib) and longer-term frontline data with venetoclax/azacitidine, supporting the ongoing Phase 3 KOMET-017 study. The data expands the potential addressable AML population beyond NPM1-mutated and KMT2A-rearranged subtypes.

Key Facts

  • Eight abstracts on ziftomenib accepted for 2026 ASH Annual Meeting (Dec 12-15, New Orleans)
  • Includes first clinical results for ziftomenib + quizartinib in newly diagnosed NPM1/FLT3 co-mutated AML
  • Includes first clinical results for ziftomenib + gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML
  • Longer-term data for ziftomenib + venetoclax/azacitidine in frontline AML supports Phase 3 KOMET-017
  • Exploratory analysis of ziftomenib activity in AML subtypes beyond NPM1-mutated and KMT2A-rearranged
  • Pediatric data from ITCC-101/APAL2020K trial evaluating ziftomenib with fludarabine/cytarabine
  • Investor webcast scheduled for December 15, 2026 at 8:30 a.m. ET

Financial Impact

No financial figures disclosed; data readout may influence future revenue potential of ziftomenib, which is already FDA-approved for R/R NPM1-mutated AML

pipeline valuepotential market expansion

Risk Factors

  • Preliminary data may change with longer follow-up or larger patient numbers
  • Early-stage combination data may not predict Phase 3 outcomes
  • Differentiation syndrome and QTc prolongation are known safety risks for ziftomenib
  • Competition from other menin inhibitors in development

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3395401

Track record

29 reports on KURA

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  2. Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  4. Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  5. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Viewing Entry $7.61 Now $7.09 −6.83% settles Feb 2
  7. Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
  8. Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
  9. Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
  10. Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026